CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Socie
May 16, 2025 06:00 ET | Source: CAMP4 Therapeutics Haploinsufficient SYNGAP1 mice…
Databricks Unveils Data Intelligence for Marketing
A unified data and AI foundation that brings together all customer and…
Life Moments, in partnership with Relevant Software, launches AI Coaching Agent for financial institutions
LVIV, Ukraine, May 12, 2025 (GLOBE NEWSWIRE) -- Life Moments, a UK…
Engadin 2025: athletes sharing competition footage, and Werners viral video, take social media interest to record heights
Apr 16, 2025 - The FIS Snowboard, Freestyle and Freeski World Championships…
CleverTap and ETBrandEquity Return with Season 4 of ‘The Big Leap’
Insights into customer behavior have always been the key to successful customer…
U. S. Steel Issues Updated Letter to Stockholders
PITTSBURGH--(BUSINESS WIRE)--United States Steel Corporation ("U. S. Steel" or the “Company”) (NYSE:…
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope
March 25, 2025 16:05 ET | Source: Elutia Inc. — Rigorous testing…
Telefnica Tech and IBM sign a collaboration agreement for quantum-safe technology
Telefónica Tech to integrate IBM quantum safe technology into its cybersecurity services…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
Weiss Asset Management LP UK Regulatory Announcement: Form 8.3 – Smith (DS) plc
BOSTON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON…